An interventional study of Oral iron in Atopic Dermatitis, sponsored by Cairo University. Not yet recruiting. Open to participants aged 12 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The present randomized controlled trial aims to evaluate the effect of adjunctive oral iron supplementation on disease severity and quality of life in adolescents with mild to moderate atopic dermatitis. In addition, the study will explore whether baseline iron status modifies treatment response and whether changes in iron biomarkers correlate with improvements in clinical severity scores.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
This study's planned enrollment of 124 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Iron-related exclusions
Use of oral or intravenous iron supplementation within the previous three months.
Hematologic exclusions
Use of systemic treatments for atopic dermatitis, including:
Systemic exclusions
Severe chronic illnesses that may affect study participation or safety, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard-of-care topical therapy (emollients and steroids). Standard topical therapies for atopic dermatitis will be continued and documented.
Participants will receive (Ferrodunal capsules providing 100 mg elemental oral iron once daily) in addition to standard-of-care topical therapy (emollients and steroids). The 100 mg fixed dose falls within the recommended paediatric dosing range of 3-6 mg/kg/day for most adolescents weighing ≥20 kg. Iron supplementation will be discontinued if serum ferritin exceeds 300 ng/mL on two consecutive measurements.
Dietary Supplement: Oral iron
Ferrodunal capsules providing 100 mg elemental oral iron once daily
• Change in Eczema Area and Severity Index (EASI) score from baseline to week 12.
Higher scores indicate more severe atopic dermatitis, Minimum score is 0 and maximum is 72.
Time frame: 12 weeks
Change in SCORing Atopic Dermatitis (SCORAD) score from baseline to weeks 6 and 12.
Higher scores indicate more severe disease and symptoms. Maximum score is 103 and minimum is zero.
Time frame: 12 weeks
Change in Children's Dermatology Life Quality Index (CDLQI) from baseline to weeks 6 and 12.
Higher scores indicate greater impairment in quality of life. Score from 0 to 30.
Time frame: 12 weeks
Change in Patient-Oriented Eczema Measure (POEM) from baselines to weeks 6 and 12.
Higher scores indicate worse eczema symptoms. Maximum score is 28 and minimum is 0.
Time frame: 12 weeks
Change in EuroQol Visual Analogue Scale (EQ-VAS) from baseline to weeks 6 and 12.
Higher scores indicate better perceived overall health. Score is from 0 to 100.
Time frame: 12 weeks
Change in Peak Pruritus Numerical Rating Scale (PP-NRS) from baseline to weeks 6 and 12.
Higher scores indicate more severe itching. Score is from 0 to 10.
Time frame: 12 weeks
Change in serum ferritin from baseline to weeks 6 and 12.
Time frame: 12 weeks
Proportion of participants achieving EASI-50, EASI-75, and EASI-90.
Time frame: 12 weeks
Adverse events frequency
Time frame: 12 weeks
Medication adherence will be assessed through capsule counts at each follow-up visit.
Time frame: 12 weeks
Correlation between baseline iron status strata and EASI score. (exploratory outcome)
Time frame: 12 weeks
Correlation between change in iron biomarkers and change in EASI score. (exploratory outcome)
Time frame: 12 weeks
Change in EQ-5D-Y index score from baseline to weeks 6 and 12.
Higher scores indicate better health-related quality of life. Usually ≤1 (can be negative in some tariffs).
Time frame: 12 weeks
Change in serum iron from baseline to weeks 6 and 12.
Time frame: 12 weeks
Change in serum hemoglobin from baseline to weeks 6 and 12.
Time frame: 12 weeks
Change in serum CRP from baseline to weeks 6 and 12.
Time frame: 12 weeks
Medication adherence will be assessed through participant self-report at each follow-up visit.
Time frame: 12 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jun 2027, 13 months later.
Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 13 months is below that.
Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron